Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
1997-7-7
|
| pubmed:abstractText |
This study was designed to investigate the influence of the calcium (Ca2+) channel inhibitors nicardipine, nifedipine, and flunarizine on the protective action of MK-801, LY 235959 [N-methyl-D-aspartate (NMDA) receptor antagonists], and GYKI 52466 (a non-NMDA receptor antagonist) against electroconvulsions in mice. Unlike nicardipine (15 mg/kg) or flunarizine (10 mg/kg) nifedipine (7.5 and 15 mg/kg) potentiated the protective potency of MK-801 (0.05 mg/kg), as reflected by significant elevation of the convulsive threshold (a CS50 value of the current strength in mA producing tonic hind limb extension in 50% of the animals). The protective activity of LY 235959 and GYKI 52466 was reflected by their ED50 values in mg/kg, at which the drugs were expected to protect 50% of mice against maximal electroshock-induced tonic extension of the hind limbs. Nicardipine (3.75 15 mg/kg), nifedipine (0.94-15 mg/kg), and flunarizine (2.5-10 mg/kg) in a dose-dependent manner markedly potentiated the antiseizure efficacy of LY 235959. Flunarizine (5 and 10 mg/kg) was the only Ca2+ channel inhibitor to enhance the protective action of GYKI 52466 against electroconvulsions. Except with MK-801 + flunarizine (motor performance) or GYKI 52466 + flunarizine (long-term memory), combination of NMDA or non-NMDA receptor antagonists with Ca2+ channel inhibitors produced an impairment of motor performance (evaluated in the chimney test) and long-term memory acquisition (measured in the passive avoidance task) as compared with vehicle treatment.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Anxiety Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Anticonvulsants,
http://linkedlifedata.com/resource/pubmed/chemical/Benzodiazepines,
http://linkedlifedata.com/resource/pubmed/chemical/Calcium Channel Blockers,
http://linkedlifedata.com/resource/pubmed/chemical/Dizocilpine Maleate,
http://linkedlifedata.com/resource/pubmed/chemical/Excitatory Amino Acid Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Flunarizine,
http://linkedlifedata.com/resource/pubmed/chemical/GYKI 52466,
http://linkedlifedata.com/resource/pubmed/chemical/Isoquinolines,
http://linkedlifedata.com/resource/pubmed/chemical/LY 235959,
http://linkedlifedata.com/resource/pubmed/chemical/Nicardipine,
http://linkedlifedata.com/resource/pubmed/chemical/Nifedipine
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
0091-3057
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
56
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
629-35
|
| pubmed:dateRevised |
2008-11-21
|
| pubmed:meshHeading |
pubmed-meshheading:9130287-Animals,
pubmed-meshheading:9130287-Anti-Anxiety Agents,
pubmed-meshheading:9130287-Anticonvulsants,
pubmed-meshheading:9130287-Avoidance Learning,
pubmed-meshheading:9130287-Benzodiazepines,
pubmed-meshheading:9130287-Calcium Channel Blockers,
pubmed-meshheading:9130287-Dizocilpine Maleate,
pubmed-meshheading:9130287-Drug Interactions,
pubmed-meshheading:9130287-Electroshock,
pubmed-meshheading:9130287-Excitatory Amino Acid Antagonists,
pubmed-meshheading:9130287-Flunarizine,
pubmed-meshheading:9130287-Isoquinolines,
pubmed-meshheading:9130287-Male,
pubmed-meshheading:9130287-Mice,
pubmed-meshheading:9130287-Motor Activity,
pubmed-meshheading:9130287-Nicardipine,
pubmed-meshheading:9130287-Nifedipine,
pubmed-meshheading:9130287-Seizures
|
| pubmed:year |
1997
|
| pubmed:articleTitle |
Anticonvulsant and adverse effects of MK-801, LY 235959, and GYKI 52466 in combination with Ca2+ channel inhibitors in mice.
|
| pubmed:affiliation |
Department of Pharmacology, Medical University School, Lublin, Poland. mgasior@irp.nih.nida.gov
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|